Longboard Pharmaceuticals to Participate in Maxim Group 2022 Virtual Growth Conference
March 22 2022 - 4:01PM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that Kevin Lind, Longboard’s President & Chief Executive
Officer, will present at the Maxim Group LLC Virtual Growth
Conference, taking place March 28–30, 2022.
The presentation will be available to registered
users via M-Vest, a division of Maxim Group LLC, from Monday, March
28, at 9:00 AM, through Wednesday, March 30, at 5:00 PM ET.
Registration is required for conference participation. Registration
and access to the presentation can be found here.
To access an archived webcast of the
presentation following the event, please visit the “Events &
Presentations” page within the Investors Relations section of
Longboard’s website at https://www.longboardpharma.com/. The
presentation will become available after the conference concludes
and archived on the website for at least 30 days.
About the Maxim Growth
Conference
During this virtual conference, investors will
hear from executives from a wide range of sectors including
Biotech, Clean Energy, Electric Vehicles, Financial Services,
Fintech & REITS, Gaming & Entertainment, Healthcare,
Healthcare IT, Infrastructure, Shipping and Technology/
Media/Telecom. The conference will feature company presentations,
fireside chats, roundtable discussions, and live Q&A with CEOs
moderated by Maxim Research Analysts.
About Longboard
Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on developing
novel, transformative medicines for neurological diseases.
Longboard is working to advance a portfolio of centrally acting
product candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of
GPCR research. Longboard is evaluating LP352, an oral, centrally
acting 5-hydroxytryptamine 2c (5-HT2c) receptor superagonist, with
negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes,
in development for the potential treatment of seizures associated
with a broad range of developmental and epileptic encephalopathies.
Longboard is also evaluating LP659, a centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
in development for the potential treatment of multiple neurological
diseases, and LP143, a centrally acting, full cannabinoid type 2
receptor (CB2) agonist, in development for the potential treatment
of central nervous system (CNS) diseases and disorders.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Longboard’s
participation in the upcoming conference, Longboard’s clinical and
preclinical programs, ability to develop and deliver medicines, and
focus. For such statements, Longboard claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or
results may differ materially from Longboard’s expectations.
Factors that could cause actual results to differ materially from
those stated or implied by Longboard’s forward-looking statements
are disclosed in Longboard’s filings with the Securities and
Exchange Commission (SEC). These forward-looking statements
represent Longboard’s judgment as of the time of this release.
Longboard disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024